Pancoast tumour and Horner syndrome represents a specialized, highly distinctive clinical entity characterized by primary bronchogenic carcinoma arising in the pulmonary apex (superior sulcus) with direct local extension into surrounding chest wall structures, neural elements, and vascular channels 1, 2. First systematically described by Henry K. Pancoast in 1924 and 1932, these superior sulcus tumours typically present not with classic pulmonary symptoms like cough or hemoptysis, but rather with severe somatic and neuropathic pain in the shoulder and upper extremity, often accompanied by the characteristic oculosympathetic interruption known as Horner syndrome 2, 7. Because of their unique anatomical localization near the thoracic inlet—encroaching upon the lower trunk of the brachial plexus, subclavian vessels, first and second ribs, and the sympathetic chain—these neoplasms require an aggressive multidisciplinary therapeutic approach combining advanced diagnostic imaging, induction chemoradiotherapy, and complex thoracic surgical resection 1, 4.
Etiology & Risk Factors
- Histological Classification: Over 95% of Pancoast tumours are non-small cell lung carcinomas (NSCLCs) 2. Squamous cell carcinoma is the most frequent histological subtype, accounting for approximately 50% of cases, followed by adenocarcinoma (30% to 40%) and large cell carcinoma (10%) 1, 2. Small cell lung cancer occasionally presents in an apical location but rarely produces the classic superior sulcus syndrome.
- Tobacco Use: Cigarette smoking remains the primary etiological risk factor, directly linked to the pathogenesis of primary bronchogenic malignancies through carcinogen-induced DNA mutations in bronchial epithelial cells.
- Environmental and Occupational Exposures: Chronic occupational inhalation of asbestos, radon gas, nickel, arsenic, chromium, and polycyclic aromatic hydrocarbons significantly magnifies oncogenic risk, particularly in cigarette smokers.
- Genetic Predisposition: Familial aggregation, inherited tumor suppressor gene mutations (such as p53 or KRAS alterations), and impaired DNA damage repair mechanisms contribute to baseline malignant transformation in the pulmonary apex.
Pathophysiology
The pathophysiology of a Pancoast tumour stems directly from its restricted anatomical cradle at the thoracic inlet, where vital neurovascular and skeletal structures are tightly packed. Originating in the peripheral pulmonary parenchyma of the lung apex, the expanding neoplasm breaches the visceral and parietal pleura, invading the endothoracic fascia and adjacent apical chest wall 1, 3.
The tumour progressively destroys the periosteum and cortex of the first and second ribs, as well as the adjacent thoracic vertebral bodies (typically T1-T3) 1, 2, 3. As the mass expands inferiorly and posteriorly, it directly involves the lower trunk of the brachial plexus (composed of the C8 and T1 nerve roots), generating severe, unremitting neuropathic pain radiating down the medial arm and forearm, coupled with intrinsic hand muscle wasting 7. Concurrently, invasion or encasement of the cervical sympathetic chain—specifically the inferior cervical ganglion and the stellate ganglion (fusion of the inferior cervical and first thoracic sympathetic ganglia)—disrupts the three-neuron oculosympathetic pathway, producing the classic clinical constellation of Horner syndrome (ipsilateral miosis, partial ptosis, and facial anhidrosis) 1, 2, 6. Vascular invasion of the subclavian artery, subclavian vein, or brachiocephalic vessels can precipitate upper extremity edema, venous thrombosis, or subclavian steal physiology 1, 2.
Clinical Presentation & Classic Clinical Signs
- History & Cardinal Symptoms:
- Shoulder and Scapular Pain: The most common presenting symptom (occurring in over 90% of patients), described as a deep, dull, relentless ache localized to the shoulder, scapula, and axilla, frequently misdiagnosed initially as cervical radiculopathy, bursitis, or rotator cuff tendonitis 4, 7.
- Radicular Upper Extremity Pain: Severe, sharp, burning neuropathic pain radiating down the medial aspect of the arm, forearm, and hand along the C8-T2 dermatomal distributions 7.
- Weakness and Muscle Wasting: Progressive atrophy of the intrinsic muscles of the hand (thenar and hypothenar eminences, interosseous muscles) due to chronic compression and destruction of the lower brachial plexus trunk 7.
- Systemic Malignant Symptoms: Unintentional weight loss, anorexia, fatigue, and occasional low-grade fever. Standard pulmonary symptoms such as productive cough, dyspnea, or hemoptysis are notably absent or late in onset because the primary tumour is small and peripheral.
- Physical Examination & Named Clinical Signs:
- Horner Syndrome: Characterized by ipsilateral triad of miosis (constricted pupil due to loss of sympathetic dilator pupillae innervation), partial ptosis (drooping of the upper eyelid secondary to paralysis of the superior tarsal muscle of Müller), and facial anhidrosis (absence of sweating on the ipsilateral side of the face and neck due to interruption of sympathetic sudomotor fibers) 6, 7.
- Pancoast-Tobias Syndrome: The classic clinical complex comprising severe shoulder/arm pain, ipsilateral Horner syndrome, and intrinsic hand muscle atrophy resulting from superior sulcus tumour invasion 7.
- Supraclavicular Mass & Adenopathy: Palpable, firm, fixed supraclavicular lymphadenopathy or a direct palpable apical mass in advanced cases.
- Vascular Signs: Edema of the ipsilateral upper extremity, superficial venous distension across the shoulder girdle, or diminished radial pulses if the subclavian vessels are compressed or thrombosed.
Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)
| Diagnostic Modality / Test | Expected Clinical & Radiological / Laboratory Finding |
|---|---|
| Gold-Standard Investigation | Contrast-enhanced chest and neck MRI (for evaluating soft-tissue extension, brachial plexus encasement, vertebral body involvement, and spinal canal invasion) combined with CT-guided percutaneous core needle biopsy or diagnostic bronchoscopy for histological verification 1, 2. |
| Laboratory Panel | Complete blood count (evaluating for anemia of chronic disease or leukocytosis), comprehensive metabolic panel (assessing renal and hepatic function prior to chemotherapy, checking for hypercalcemia of malignancy secondary to PTHrP secretion), and coagulation profile. |
| Imaging / Radiology (X-ray, US, CT, MRI) | Chest radiography frequently demonstrates an asymmetric apical cap, pleural thickening, or apical mass (often subtle and easily missed). Contrast-enhanced chest CT delineates primary pulmonary mass dimensions, rib lysis, mediastinal lymph node enlargement, and vascular encasement. MRI provides superior multiplanar visualization of neural foramina, spinal cord compression, and brachial plexus invasion 1, 2, 3. |
| ECG / Histopathology / Procedural | 12-lead ECG for pre-operative cardiac risk stratification. Histopathological and immunohistochemical analysis (e.g., TTF-1, p40, CK5/6) confirming non-small cell lung cancer subtype. Mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for precise mediastinal lymph node staging 4, 5. |
Staging, Classification & Clinical Scoring Systems
| Criterion / Stage / Score Component | Clinical Threshold, Points & Management Implication |
|---|---|
| TNM Staging (T Status) | T3: Tumour of any size invading directly the chest wall (including first and second ribs), lower brachial plexus, or mediastinal pleura without invading the heart, great vessels, trachea, esophagus, or vertebral body. T4: Tumour invading the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, or carina, or with separate tumour nodule(s) in a different ipsilateral lobe. Determines resectability and surgical approach 3, 4. |
| Nodal Staging (N Status) | N0: No regional lymph node metastases. N1: Ipsilateral peribronchial and/or ipsilateral hilar lymph nodes. N2: Ipsilateral mediastinal and/or subcarinal lymph node metastasis. N3: Contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene, or supraclavicular lymph node metastasis. N2/N3 disease historically precluded primary resection, though modern induction chemoradiotherapy protocols permit selective resection in controlled N2 disease 3, 4. |
| M Staging (M Status) | M0: No distant metastasis. M1a/b/c: Distant metastasis present. Presence of distant metastasis (M1) is an absolute contraindication to curative-intent surgical resection; management shifts to palliative systemic therapy and radiation. |
| Resectability Assessment | Comprehensive evaluation of anatomical involvement: unresectable features include extensive brachial plexus invasion above T1 root, encasement of the main subclavian vessels >180 degrees, spinal canal invasion with cord compression, and contralateral mediastinal lymph node involvement 1, 3, 4. |
Differential Diagnosis
| Differential Condition | Distinguishing Clinical, Biochemical & Imaging Features |
|---|---|
| Cervical Radiculopathy & Disc Disease | Presents with neck and arm pain, but lacks Horner syndrome, apical pulmonary mass on imaging, and systemic constitutional symptoms. MRI reveals degenerative disc disease or nerve root impingement without destructive apical soft-tissue masses. |
| Thoracic Outlet Syndrome (TOS) | Characterized by upper extremity pain, paresthesias, and vascular compromise caused by compression of the brachial plexus or subclavian vessels within the thoracic outlet (e.g., cervical rib). Distinguished from Pancoast tumours by the absence of malignant lung parenchymal lesions, progressive constitutional decline, and Horner syndrome. |
| Apical Tuberculosis or Fungal Infection | Infectious apical pulmonary cavitary lesions (e.g., Mycobacterium tuberculosis, Aspergillus species) can mimic Pancoast tumours on chest radiography. Differentiated by positive sputum acid-fast bacilli smears, fungal cultures, specific serology, and lack of true infiltrative neoplastic bone destruction. |
| Superior Sulcus Schwannoma / Neurogenic Tumour | Benign or malignant nerve sheath tumours arising from the brachial plexus or intercostal nerves in the thoracic apex. Distinguished on histopathology and imaging by their neural origin, absence of primary bronchial mucosal involvement, and distinct neurogenic imaging characteristics. |
Management & Treatment Protocol
- Initial Stabilization & Resuscitation:
- Assess and secure airway, breathing, and circulation. Administer supplemental oxygen if hypoxemic.
- Initiate aggressive multimodal analgesic therapy for intractable neuropathic pain, incorporating non-opioid analgesics, gabapentinoids (e.g., gabapentin titrated to 300 mg to 900 mg orally three times daily), and short-term opioid therapy under palliative care guidance.
- First-Line Medical / Pharmacological Therapy (with exact adult dosing):
- Induction Chemoradiotherapy (Standard of Care): Concurrent platinum-based chemotherapy combined with thoracic radiotherapy administered prior to surgical resection 1, 4.
- Chemotherapy Regimen: Cisplatin 50 mg/m² intravenous infusion on days 1, 8, 29, and 36, combined with etoposide 50 mg/m² intravenous infusion daily on days 1 to 5 and 29 to 33, administered concurrently with radiation. Alternatively, weekly paclitaxel (45 to 50 mg/m² IV) and carboplatin (AUC 2 IV) administered concurrently with radiation.
- Radiotherapy Dosing: Total radiation dose of 45 Gy to 50.4 Gy delivered in 1.8 Gy to 2.0 Gy daily fractions over 5 weeks to the primary tumour and regional lymphatics.
- Surgical / Interventional Indications:
- En Bloc Surgical Resection: Performed 3 to 6 weeks following completion of induction chemoradiotherapy in patients with localized or locally advanced resectable disease (T3-4 N0-1 M0) and adequate physiological reserve 1, 4.
- Surgical Approach: Tailored surgical access (e.g., Shaw-Paulson posterior-lateral thoracotomy, Dartevelle anterior transcervico-thoracic approach, or Grunenwald transmanubrial osteomuscular approach) to achieve complete negative margins (R0 resection) by removing the upper lobe of the lung, chest wall en bloc (first and second ribs), invaded vertebral elements, and involved neural or vascular structures 1, 2, 3.
Complications & Prognosis
- Complications:
- Permanent neurological deficits, including chronic neuropathic pain syndromes, phrenic nerve palsy resulting in diaphragmatic paralysis, recurrent laryngeal nerve injury leading to vocal cord paralysis and hoarseness, and persistent Horner syndrome 2, 6.
- Postoperative thoracic complications including bronchopleural fistula, empyema, chylothorax, respiratory failure, pneumonia, and hemorrhage from great vessel dissection.
- Prognosis and Survival:
- Historically considered universally fatal with a median survival of less than one year under supportive care alone 1, 3.
- With contemporary trimodality therapy (induction chemoradiotherapy followed by radical surgical resection), 5-year survival rates range from 44% to over 50% in patients achieving complete (R0) surgical resection and pathologically confirmed complete response 1, 4.
- Key adverse prognostic indicators include incomplete surgical resection (R1/R2 margins), mediastinal lymph node involvement (N2 disease), presence of Horner syndrome prior to treatment, and advanced T4 structural invasion 3, 4.